Teva Pharmaceutical Industries (TEVA) to Release Quarterly Earnings on Wednesday

Teva Pharmaceutical Industries (NYSE:TEVA) is projected to release its Q4 2025 results before the market opens on Wednesday, January 28th. Analysts expect Teva Pharmaceutical Industries to post earnings of $0.65 per share and revenue of $4.3647 billion for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, January 28, 2026 at 8:00 AM ET.

Teva Pharmaceutical Industries Price Performance

Shares of Teva Pharmaceutical Industries stock opened at $31.38 on Wednesday. The firm has a market cap of $35.99 billion, a PE ratio of 52.30, a P/E/G ratio of 1.82 and a beta of 0.66. Teva Pharmaceutical Industries has a twelve month low of $12.47 and a twelve month high of $33.42. The company has a quick ratio of 0.82, a current ratio of 1.11 and a debt-to-equity ratio of 2.31. The business has a 50-day moving average price of $29.27 and a 200 day moving average price of $22.35.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, CAO Amir Weiss sold 12,300 shares of the stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $30.20, for a total value of $371,460.00. Following the completion of the sale, the chief accounting officer owned 5,650 shares of the company’s stock, valued at approximately $170,630. This trade represents a 68.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Roberto Mignone sold 77,400 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $30.24, for a total value of $2,340,576.00. Following the transaction, the director owned 367,600 shares in the company, valued at approximately $11,116,224. The trade was a 17.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 622,060 shares of company stock worth $17,076,965 in the last 90 days. 0.55% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of hedge funds have recently modified their holdings of TEVA. Cerity Partners LLC grew its position in shares of Teva Pharmaceutical Industries by 2.9% during the second quarter. Cerity Partners LLC now owns 45,837 shares of the company’s stock worth $768,000 after buying an additional 1,291 shares in the last quarter. Focus Partners Wealth raised its holdings in Teva Pharmaceutical Industries by 4.5% in the first quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock valued at $616,000 after acquiring an additional 1,739 shares in the last quarter. AQR Capital Management LLC lifted its stake in Teva Pharmaceutical Industries by 24.6% in the first quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock worth $368,000 after acquiring an additional 4,732 shares during the last quarter. Franklin Resources Inc. grew its holdings in Teva Pharmaceutical Industries by 12.2% during the 3rd quarter. Franklin Resources Inc. now owns 17,075 shares of the company’s stock worth $345,000 after acquiring an additional 1,850 shares in the last quarter. Finally, State of Wyoming purchased a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at approximately $299,000. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have recently commented on TEVA. Scotiabank began coverage on Teva Pharmaceutical Industries in a research report on Friday, December 5th. They issued a “sector outperform” rating and a $35.00 price objective for the company. Barclays initiated coverage on shares of Teva Pharmaceutical Industries in a report on Tuesday, December 9th. They issued an “overweight” rating and a $35.00 price target for the company. UBS Group increased their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. Jefferies Financial Group lifted their target price on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Finally, The Goldman Sachs Group boosted their target price on shares of Teva Pharmaceutical Industries from $31.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. Three investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries has an average rating of “Buy” and an average price target of $33.67.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.